The stock price of 160 Health (02656.HK) fell rapidly after breaking HKD 150 in March 2026, closing at HKD 44.42 on April 13, with over HKD 35 billion in market value evaporating from its peak. The company recently released its 2025 annual report, showing revenue of HKD 652 million (+5.02%) and an adjusted net income of approximately HKD 4.061 million, successfully turning a profit. Relying on its "Platform + AI Agent + Operations" model, it achieved "160 AI Hospital" cooperation with 82 public hospitals in 2025. However, facing the intensive layout of tech giants like Baidu (DoctorClaw) and Alibaba Health (Hydrogen Ion) in the Medical AI Agent track, the company faces severe challenges.
On April 13, HGTECH Company Limited submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities serving as the sole sponsor. The company was listed on the Main Board of the Shenzhen Stock Exchange in 2000 (000988.SZ). As the first listed company in China's laser industry, HGTECH relies on its profound accumulation in the optoelectronic information field and is committed to becoming a global leading enabler of full-stack artificial intelligence capabilities. Its business covers three major segments: optical interconnection, intelligent sensing and intelligent manufacturing, forming a complete intelligent closed loop of "sense-transmit-analyze-apply".
Victory Giant Technology (Huizhou) Co., Ltd.（02476.HK） officially launched its H-share IPO on April 13, 2026, with an offer price set at HK$209.88 per share, 100 shares per lot and an entry fee of approximately HK$21,199.67.The company is expected to list on the Main Board of the Hong Kong Stock Exchange on April 21, 2026.It plans to issue 83.34 million shares globally, raising approximately HK$17.287 billion.
Diagens (02526.HK) was listed on March 30, 2026. As the "first medical imaging LLM stock" on the HKEX, its share price soared over 200% within two weeks, closing at HKD 300 on April 10. The company’s core product, AI AutoVision®, is the first chromosome karyotype analysis system in China to receive the "Class III Innovative Medical Device" designation, improving analysis efficiency by approximately 12 times. It currently holds a 30.6% market share, ranking first in the country. In 2025, total revenue was approximately RMB 164 million (+133.72%), while the net loss expanded to RMB 67.14 million. The company's market capitalization has surpassed HKD 24 billion, with a price-to-sales (P/S) ratio exceeding 130x, far beyond the industry average.
Gpixel Changchun Microelectronics Inc. (03277.HK) officially launched its H-share IPO on April 9, 2026, with an offer price set at HK$39.88 per share, 100 shares per lot and an entry fee of approximately HK$4,028.23.The company is expected to list on the Main Board of the Hong Kong Stock Exchange on April 17, 2026.It plans to issue 65.29 million shares globally, raising approximately HK$2.504 billion.
On April 9, 2026, GenFleet Therapeutics (02595.HK) announced that its KRAS G12D inhibitor GFH375 received Breakthrough Therapy Designation (BTD) from the CDE, causing its stock price to surge 9.05% against the market trend. The drug has launched the world's first Phase III registrational study for an oral inhibitor and holds FDA Fast Track status. In 2025, the company reported revenue of RMB 130 million (+24.4% YoY). Due to fair value changes in redemption liabilities, the book net loss widened to RMB 1.795 billion, though the adjusted net loss narrowed to RMB 227 million. Its first commercial product, GFH925, saw weak early sales and faces intense global competition from over 20 rival candidates.
SAINT BELLA Group (02508.HK) recently released its first full annual report for 2025, with revenue reaching RMB 1.046 billion (+31.0%) and adjusted net profit at RMB 125 million. Despite the flagship brand’s ASP rising to RMB 267,000 and the company’s intensive recent positioning in AI LLMs and embodied intelligence funds, its stock performance remains weak. As of April 8, 2026, it closed at HKD 4.11, down approximately 37.54% from its issue price. Even as the leader in the high-end market, SAINT BELLA must still prove to investors its "anti-cyclical" ability to maintain long-term profitability amidst a service-intensive model and its transition into the AI space.
OneRobotics (06600.HK) recently released its first annual report since listing. In 2025, the company achieved revenue of RMB 900 million (+47.7% YoY) and an adjusted net profit of RMB 12.766 million, crossing the profitability threshold. The core business focuses on AI embodied home robots, which contribute nearly 90% of revenue, almost all of which is generated overseas. To expand the brand and educate the market, sales expenses surged 81.3% to RMB 312 million, significantly outstripping revenue growth. The company recently made a strategic investment of RMB 241 million for a 21% stake in Hitbot, strengthening its R&D in core components like dexterous hands and robotic arms.
BUSY MING (01768.HK), the first volume snack retail stock on the Hong Kong market, released its first annual report showing strong growth. In 2025, the company achieved revenue of RMB 66.17 billion (+68.2%) and net profit of RMB 2.329 billion (+180.9%), with gross margin rising to 9.8%. The total store count reached 21,948 (99.9% franchised), with 7,813 new franchised stores opened in 2025 at an average of 21.4 per day. As the market enters the "3.0 era," competition has shifted toward profitability quality. Institutions warn that same-store sales are under downward pressure, and the payback period has lengthened from 1–2 years to 2–3 years.
Singapore's ETF market surpassed S$18bn in AUM, with S$2.4bn net inflows in 2025 and 69% ADT growth. It covers local equities, gold, bonds, REITs, plus AI and fintech themes. NewTimeSpace Research views its “local+global” structure as a transparent window for cross-border allocation.
Youibot refiled its Hong Kong IPO application on March 31, 2026, aiming to become the "first mobile manipulation robot stock." By 2024 revenue, it ranked first in the global industrial mobile manipulation robot market. Shareholders include SoftBank Ventures Asia and IDG Capital.
The first annual report of AUX Electric (02580.HK) since its listing reflects significant operational challenges. Although revenue exceeded RMB 30 billion (+0.97%) in 2025, net profit attributable to the parent company fell sharply by 23.2% to RMB 2.235 billion. Profitability is under pressure, with the net profit margin sliding from 10% in 2023 to 7.44%. Hit by soaring costs for raw materials like copper (+34.3%) and refrigerants, its core "low-price strategy" has seen margins squeezed to the limit by cost inflation and technical bottlenecks. As of April 2, 2026, the company’s share price closed at HK$9.53, a cumulative decline of over 45% from the HK$17.42 offer price.
Ab&B Bio-Tech (02627.HK) announced a trading suspension effective April 1, 2026, due to incomplete audit procedures regarding fund investments and consultancy payment verifications. Although the earnings preview estimated 2025 revenue at RMB 446–493 million (up ~72%-90% YoY) with narrowed losses, the share price plunged approximately 58.94% in the 14 trading days prior to suspension due to profit-taking following its inclusion in the Stock Connect. The company is heavily dependent on its core product, the quadrivalent influenza subunit vaccine "Huierkangxin®," which contributes approximately 99% of its total revenue, indicating an extremely concentrated income source.
CaoCao Inc. (02643.HK) recently released its 2025 annual report, showing total revenue of RMB 20.2 billion (+37.7%) and a narrowed net loss of RMB 614 million, with adjusted profit turning positive in the fourth quarter for the first time. However, these results failed to lift the stock in the secondary market; as of March 31, 2026, it closed at HK$25.60, down nearly 39% from its IPO price. Core operational and structural challenges remain: the company is highly dependent on aggregation platforms for over 85% of its orders, with RMB 8.40 of every RMB 100 in revenue flowing to external platforms, significantly eroding profit margins.
Distinct Healthcare (02677.HK) recently disclosed its 2025 financial results, with revenue reaching RMB 1.065 billion (+11.1% YoY) and net profit hitting RMB 135 million (+61.2% YoY). Despite reaching a profitability turning point, the stock has continued to slide. As of March 30, 2026, it closed at HK$38.26, a decline of approximately 36.13% from its offer price of HK$59.90. As China’s third-largest private mid-to-high-end integrated medical institution, its market share is only 2.0%. Physical medical services contribute over 92% of revenue, while revenue growth is slowing and remains highly dependent on the Tier-1 markets of Beijing, Shanghai, Guangzhou, and Shenzhen (accounting for >70%).
As the world’s first autonomous driving benchmark with a "US + HK" dual primary listing, Pony AI (02026.HK) closed at HK$74.6 on March 27, 2026, down over 46% from its offer price. Despite 2025 revenue hitting $90 million (+20% YoY) and a significantly narrowed GAAP net loss, the capital market remains cautious about its financial health. The company’s adjusted non-GAAP net loss expanded to $174 million in 2025, with a net operating cash outflow of $165 million, indicating it has yet to close the "self-sustaining" loop.
